Ardena cements growth and expansion with new HQ

12 Nov 2018

Larger headquarters will enable the company to free up space for additional laboratories and further expand capabilities.

CDMO Ardena has cemented a sustained period of growth with a move to expanded headquarters in Gent, Belgium.

Ardena cements growth and expansion with new HQ

Since 2015, Ardena has grown from 40 to 250 staff members and seen more than 20% organic growth per year, fueled by the CDMO’s M&A strategy which has seen four acquisitions in the past 2 years, most recently Netherlands-based ChemConnection and Sweden-based Syntagon.

It now operates across six sites in Belgium, the Netherlands, Sweden and Latvia and boasts a global reach, servicing more than 300 customers in Europe, the US, Japan and Korea.

Ardena offers integrated drug development services encompassing drug substance and drug product development, clinical manufacturing, clinical logistics, full product analytical and bioanalytical support and regulatory dossier development. The company is also a leader in nanomedicine technology.

Harry Christiaens, CEO at Ardena said: “After several acquisitions and an ongoing growth period, we are firmly on track to reach our €35 million sales target for 2018 as part of our wider strategy to become a leading integrated drug development company.

“This new, larger headquarters will enable us to free up space for additional laboratories at our other sites and further expand our capabilities. It will also provide a base for our staff training centre to ensure we develop our team.

“As we move into 2019, we look forward to continued international success and carrying on with our acquisition strategy to further strengthen our service offering.”

Ardena was formed in 2017, following the merging of three companies with complementary drug development capabilities: Pharmavize in Belgium, and Crystallics and Analytical Biochemical Laboratory (ABL) in the Netherlands.

Read More

Related news

Can the industry really claim it's 'business as usual'?

Can the industry really claim it's 'business as usual'?

19 May 2020

ChargePoint Technology's Chief Commercial Officer says "yes" it can.

Read more 
HKBU scientists develop technique to eliminate drug side effects

HKBU scientists develop technique to eliminate drug side effects

19 May 2020

The novel method paves the way towards the mass production of affordable therapeutic drugs that are made with recyclable materials.

Read more 
Samsung Biologics expands business continuity excellence with additional ISO 22301 certification

Samsung Biologics expands business continuity excellence with additional ISO 22301 certification

19 May 2020

The certification is expected to instill greater 'supply' trust with clients, particularly during the current pandemic.

Read more 
Vibalogics agrees to additional manufacturing for lead COVID-19 vaccine candidate of J&J unit

Vibalogics agrees to additional manufacturing for lead COVID-19 vaccine candidate of J&J unit

18 May 2020

CDMO is contracted to produce multiple clinical batches from German facility

Read more 
Pharmapack expert recommends holistic approach to sustainability

Pharmapack expert recommends holistic approach to sustainability

18 May 2020

Although the industry might be 30% along its sustainability journey, greater interoperability is needed from materials to devices.

Read more 
KND Labs earns Active Pharmaceutical Ingredients certification for CBD ingredients

KND Labs earns Active Pharmaceutical Ingredients certification for CBD ingredients

12 May 2020

Company's manufacturing methods and processes reviewed by an independent third-party auditor to ensure the products have the highest-quality ingredients possible.

Read more 
Characterizing virus and virus-like particles

Characterizing virus and virus-like particles

12 May 2020

New application study describes the separation and characterisation of adeno associated virus serotypes by AF4.

Read more 
Recipharm increases API and raw material stocks to ensure supply amid higher antibiotics demand

Recipharm increases API and raw material stocks to ensure supply amid higher antibiotics demand

12 May 2020

CDMO says it has made "notable changes" to its supply chain processes to ensure continuing supply of medicines during COVID-19 pandemic

Read more 
AI technology company launches with Novartis and Sarepta deals

AI technology company launches with Novartis and Sarepta deals

11 May 2020

Collaborations focus on gene therapies for serious eye and muscle diseases using Dyno’s CapsidMap artificial intelligence platform to design AAV vectors.

Read more 
Demand for immunity products to be sustained long-term says SIRIO

Demand for immunity products to be sustained long-term says SIRIO

11 May 2020

Movement towards healthy lifestyles and preventative supplements the lasting behavioural change post COVID-19.

Read more